Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology
Shineco (NASDAQ: SISI), an iPSC technology platform manufacturer, has announced the creation of a new Biological Cell Digital Business Division to merge biological cell assets with blockchain technology. The company has appointed Mr. Lin Hongguang, former Chief Researcher at Korea Digital Currency Research Institute, as General Manager of the division.
The division aims to establish a blockchain-based ecosystem for biological cell assets management, focusing on standardized management, IPSC cell bank development, and blockchain-linking. Key objectives include improving cell asset traceability, developing equity transfer mechanisms, and enhancing global distribution efficiency of biological cell products.
The initiative seeks to enable medical institutions to allocate resources more efficiently, implement flexible payment systems, and integrate AI tools to optimize service delivery, making cell technology more accessible globally.
Shineco (NASDAQ: SISI), produttore di piattaforme tecnologiche per iPSC, ha annunciato la creazione della nuova Divisione Digitale per le Cellule Biologiche per integrare gli asset cellulari biologici con la tecnologia blockchain. L'azienda ha nominato Il Sig. Lin Hongguang, ex ricercatore capo presso l'Istituto coreano per la ricerca sulla valuta digitale, come direttore generale della divisione.
La divisione punta a costituire un ecosistema basato su blockchain per la gestione degli asset cellulari biologici, con focus sulla gestione standardizzata, lo sviluppo di banche di cellule iPSC e il collegamento alla blockchain. Tra gli obiettivi principali figurano il miglioramento della tracciabilit脿 degli asset cellulari, l'ideazione di meccanismi di trasferimento della propriet脿 e l'aumento dell'efficienza nella distribuzione globale dei prodotti a base di cellule biologiche.
L'iniziativa mira a permettere alle strutture mediche di allocare le risorse in modo pi霉 efficiente, adottare sistemi di pagamento flessibili e integrare strumenti di intelligenza artificiale per ottimizzare l'erogazione dei servizi, rendendo la tecnologia cellulare pi霉 accessibile a livello mondiale.
Shineco (NASDAQ: SISI), fabricante de plataformas tecnol贸gicas de iPSC, ha anunciado la creaci贸n de la nueva Divisi贸n Digital de C茅lulas Biol贸gicas para fusionar los activos celulares biol贸gicos con la tecnolog铆a blockchain. La compa帽铆a ha nombrado a el Sr. Lin Hongguang, ex investigador principal del Instituto de Investigaci贸n de Moneda Digital de Corea, como gerente general de la divisi贸n.
La divisi贸n pretende establecer un ecosistema basado en blockchain para la gesti贸n de activos celulares biol贸gicos, con 茅nfasis en la gesti贸n estandarizada, el desarrollo de bancos de c茅lulas iPSC y la vinculaci贸n con blockchain. Entre los objetivos clave est谩n mejorar la trazabilidad de los activos celulares, desarrollar mecanismos de transferencia de participaci贸n y aumentar la eficiencia de la distribuci贸n global de productos celulares.
La iniciativa busca permitir que las instituciones m茅dicas asignen recursos con mayor eficiencia, implementar sistemas de pago flexibles e integrar herramientas de IA para optimizar la prestaci贸n de servicios, haciendo la tecnolog铆a celular m谩s accesible a nivel mundial.
Shineco (NASDAQ: SISI)電� iPSC 旮办垹 頂岆灚韽� 鞝滌“鞐呾泊搿�, 靸濎泊靹疙彫 鞛愳偘鞚� 敫旊觳挫澑 旮办垹瓿� 瓴绊暕頃橁赴 鞙勴暣 靸堧鞖� 靸濎泊靹疙彫 霐旍韯� 靷梾攵�毳� 鞁犾劋頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 毽� 頇嶊磻 鞝� 頃滉淡霐旍韯疙喌頇旍棸甑洂 靾橃劃鞐瓣惮鞗愳潉 頃措嫻 靷梾攵�鞚� 齑濌磩毵る媹鞝�搿� 鞛勲獏頄堨姷雼堧嫟.
頃措嫻 靷梾攵�電� 靸濎泊靹疙彫 鞛愳偘 甏�毽ゼ 鞙勴暅 敫旊觳挫澑 旮半皹 靸濏儨瓿�毳� 甑稌頃橂姅 瓴冹潉 氇╉憸搿� 頃橂┌, 響滌頇旊悳 甏�毽�, iPSC 靹疙彫鞚�頄� 臧滊皽 氚� 敫旊觳挫澑 鞐半彊鞐� 欷戩爯鞚� 霊‰媹雼�. 欤检殧 氇╉憸搿滊姅 靹疙彫 鞛愳偘鞚� 於旍爜靹� 頄レ儊, 甓岆Μ 鞚挫爠 氅旍护雼堨 臧滊皽, 靸濎泊靹疙彫 鞝滍拡鞚� 旮�搿滊矊 鞙犿喌 須湪靹� 鞝滉碃 霌膘澊 韽暔霅╇媹雼�.
鞚� 鞚措媹靺旐嫲敫岆姅 鞚橂 旮瓣磤鞚� 鞛愳洂鞚� 氤措嫟 須湪鞝侅溂搿� 氚半秳頃橁碃 鞙犾棸頃� 瓴办牅 鞁滌姢韰滌潉 霃勳瀰頃橂┌ AI 霃勱惮毳� 韱淀暕頃� 靹滊箘鞀� 鞝滉车鞚� 斓滌爜頇旐暔鞙茧鞃� 靹疙彫 旮办垹鞚� 旮�搿滊矊 鞝戧芳靹膘潉 雴掛澊電� 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Shineco (NASDAQ: SISI), fabricant d'une plateforme technologique iPSC, a annonc茅 la cr茅ation d'une nouvelle Division num茅rique des cellules biologiques pour combiner les actifs cellulaires biologiques avec la technologie blockchain. La soci茅t茅 a nomm茅 M. Lin Hongguang, ancien chercheur principal 脿 l'Institut cor茅en de recherche sur la monnaie num茅rique, directeur g茅n茅ral de la division.
La division vise 脿 茅tablir un 茅cosyst猫me bas茅 sur la blockchain pour la gestion des actifs cellulaires biologiques, en se concentrant sur la gestion standardis茅e, le d茅veloppement d'une banque de cellules iPSC et la connexion 脿 la blockchain. Les objectifs cl茅s incluent l'am茅lioration de la tra莽abilit茅 des actifs cellulaires, le d茅veloppement de m茅canismes de transfert de droits/participations et l'am茅lioration de l'efficacit茅 de la distribution mondiale des produits 脿 base de cellules biologiques.
L'initiative cherche 脿 permettre aux 茅tablissements m茅dicaux d'allouer leurs ressources plus efficacement, de mettre en place des syst猫mes de paiement flexibles et d'int茅grer des outils d'IA pour optimiser la prestation de services, rendant la technologie cellulaire plus accessible 脿 l'茅chelle mondiale.
Shineco (NASDAQ: SISI), ein Hersteller von iPSC-Technologieplattformen, hat die Gr眉ndung einer neuen Digitalen Gesch盲ftseinheit f眉r biologische Zellen angek眉ndigt, um biologische Zell-Assets mit Blockchain-Technologie zu verbinden. Das Unternehmen hat Herrn Lin Hongguang, ehemaligen leitenden Forscher am Koreanischen Forschungsinstitut f眉r digitale W盲hrungen, zum General Manager der Einheit ernannt.
Die Einheit hat das Ziel, ein blockchain-basiertes 脰kosystem f眉r das Management biologischer Zell-Assets aufzubauen, mit Fokus auf standardisierte Verwaltung, den Ausbau einer iPSC-Zellbank und die Blockchain-Anbindung. Zu den zentralen Zielen geh枚ren die Verbesserung der Nachverfolgbarkeit von Zell-Assets, die Entwicklung von Mechanismen f眉r 脺bertragungen von Eigentums-/Beteiligungsrechten und die Steigerung der globalen Vertriebseffizienz biologischer Zellprodukte.
Die Initiative soll medizinischen Einrichtungen erm枚glichen, Ressourcen effizienter zuzuordnen, flexible Zahlungssysteme einzuf眉hren und KI-Werkzeuge zu integrieren, um die Dienstleistungserbringung zu optimieren und Zelltechnologien weltweit besser zug盲nglich zu machen.
- Strategic integration of blockchain technology with biological cell assets to improve efficiency
- Appointment of experienced blockchain expert Mr. Lin Hongguang as General Manager
- Potential for increased global market share through improved distribution network
- Development of new flexible payment systems to increase accessibility
- No immediate revenue impact or financial metrics provided
- Implementation timeline and costs not disclosed
- Regulatory uncertainties around blockchain integration with biological assets
Insights
Shineco's integration of blockchain with stem cell technology aims to improve asset management but faces significant implementation challenges.
Shineco (NASDAQ: SISI) has announced the creation of a new Biological Cell Digital Business Division that aims to merge its induced pluripotent stem cell (iPSC) technology with blockchain systems. The company has appointed blockchain specialist Lin Hongguang, formerly of the Korea Digital Currency Research Institute, to lead this initiative as General Manager.
The core objective is to use blockchain technology to create a more efficient ecosystem for biological cell assets through two primary mechanisms: (1) standardized management with traceability through an IPSC cell bank with blockchain verification, and (2) development of equity transfer tools to improve circulation efficiency of cell assets.
While the announcement emphasizes how this integration could potentially streamline resource allocation for medical institutions and make cell technology more accessible globally, it lacks concrete implementation details or timelines. The concept leverages blockchain's strengths in traceability and verification, which are valuable in the biological materials space where chain-of-custody and authenticity are critical.
However, this announcement represents a highly experimental approach combining two complex technologies. The biological cell industry faces genuine challenges including cross-border regulatory hurdles and complex logistics that blockchain alone cannot resolve. The company's claim that this initiative will "promote a significant increase in global market share" remains speculative without more detailed execution plans.
The selection of a blockchain specialist rather than someone with biological sciences expertise to lead this division suggests the company may be prioritizing the technological infrastructure over the specialized biological applications. This initiative appears to be in very early conceptual stages rather than an immediately operational business line.
The Division is expected to use blockchain technology to build an efficient ecosystem for managing and leveraging biological cell assets. Its primary goals are (1) to promote the standardized management of biological cell assets; to establish an induced pluripotent stem cells聽("IPSC") cell bank; to achieve blockchain-linking; to establish compliance frameworks so that biological cell assets can be clearly traced and securely confirmed; and (2) to develop supporting industry blockchain tools such as equity transfer mechanisms to address the problem of the low efficiency of cell asset circulation.
The work to be undertaken by the Division is anticipated to allow medical and research institutions to allocate resources more flexibly, and it is contemplated to lower the threshold for users to obtain services through flexible payments and other methods. In addition, the Company believes it will streamline the connection between service interfaces and storage appointments, create cross-institutional research collaborations, enhance health data management and introduce artificial intelligence ("AI") tools to optimize the service experience. A key goal of this new business initiative is to make cell technology services more accessible to global users.
Mr. Lin Hongguang, formerly Chief Researcher at the Korea Digital Currency Research Institute, has extensive experience in the blockchain and digital asset industries, providing strategic, economic modeling, and listing advisory services to numerous Web3 projects. Mr. Lin specializes in digital asset compliance, token design and international implementation, and has extensive international market resources. As General Manager, Mr. Lin will oversee the Division's strategic planning, daily operations, and team building. In addition, Mr. Lin's responsibilities include developing standards for on-chain cell asset listings, expanding global ecosystem collaborations, promoting the implementation of service scenarios, facilitating compliance filings, and ultimately contributing to the establishment of a global distribution network for biological cell products.
"Bio-cell technology is a core driving force of the 'big health' industry, but the industry currently faces challenges such as low global circulation efficiency, difficulty in cross-regional collaboration, and high user service thresholds," said Jennifer Zhan, CEO of Shineco. "We established the Biological Cell Digital Division precisely to break through these bottlenecks through a cell asset chain model. We believe this will not only enable people to more easily access cell technology services but also promote a significant increase in the global market share of Shineco's biological cell products as well as create long-term value for our shareholders. We view this endeavor as a core element of our corporate growth plan, and it represents a strategic investment in the future of the industry."
About Shineco, Inc.
Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products.聽For more information about Shineco, please visit .
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
[email protected]
Mobile: +86-010-68130220
View original content:
SOURCE Shineco,Inc.
FAQ
What is the purpose of Shineco's new Biological Cell Digital Division?
Who will lead Shineco's (SISI) new Biological Cell Digital Division?
How will blockchain technology benefit Shineco's biological cell business?
What are the main goals of Shineco's blockchain integration initiative?
How will this new division affect Shineco (SISI) shareholders?
